place Online
date_range December 3, 2024
Real-world data webinar
REGISTRATION FOR THIS WEBINAR IS NOW CLOSED This webinar introduces and explains the main concepts of the CIOMS report on Real-world data and real-world evidence in regulatory decision making. https://doi.org/10.56759/kfxh6213 The webinar recording and slides will be made available after the event.
About the event
- mic 9 Speakers
- group 1000 Places
- import_contacts 1 Topic
In May 2024, the Council for International Organizations of Medical Sciences (CIOMS) published its much anticipated consensus report on Real-world data and real-world evidence in regulatory decision making. This webinar will introduce and explain the main concepts of this report. Real-world data — for example data from electronic health records and registries — are increasingly used to complement clinical trial data to support safety and efficacy claims for medicines. The report informs discussions about the use of real-world data and real-world evidence for regulatory and health care decision making, including decisions to make a product available for use (authorisation), to cover the costs of its use (reimbursement), and to use a product for a particular patient (clinical use). This webinar is intended for medicinal product regulators, healthcare payers, health care and medicinal products industries, researchers, bioethicists, patients and health care professionals. https://doi.org/10.56759/kfxh6213
Speakers and Panelists
-
Lembit Rägo
Secretary-General, CIOMS, Switzerland
-
Alar Irs
Chief Medical Officer, State Agency of Medicines, Estonia
-
Juhaeri Juhaeri
Vice President and Global Head, Epidemiology and Benefit-Risk, Sanofi, US
-
Yoshiko Atsuta
Scientific Director, Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT), and Professor, Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Japan
-
David Townend
Professor of Health and Life Sciences Law and Associate Dean (Research and Enterprise), The City Law School, City St George’s, University of London, UK
-
Sean Hennessy
Professor of Epidemiology and of Systems Pharmacology and Translational Therapeutics / Director, Division of Epidemiology, Perelman School of Medicine, University of Pennsylvania, US
-
David Shaw
Institute for Biomedical Ethics at the University of Basel, Switzerland, and Associate Professor of Health Ethics & Law, Maastricht University, the Netherlands
-
Elodie Baumfeld Andre
Head of Real-World Data (RWD) team, Roche Information Solutions, US
-
Anja Schiel
Senior Adviser, Norwegian Medical Products Agency (NOMA), Scientific Advice Working Party, European Medicines Agency (EMA) and MPG, and JSC member HTA-Coordination Group (HTA-CG)
Webinar programme
Welcome and introduction
Lembit Rägo
Regulatory context
Alar Irs
Data sources
Juhaeri Juhaeri
Methods
Yoshiko Atsuta
Ethics and governance
David Townend
Conclusion
Sean Hennessy
Panel discussion hosted by Lembit Rägo
Speakers as above plus the panel members: Elodie Baumfeld Andre, Anja Schiel and David Shaw